Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens

The "Accelerating Discovery through Partnered Research with All of Us to Analyze Participant Biospecimens" funding opportunity is forecasted by the National Institutes of Health (NIH), specifically in connection with the All of Us Research Program. This initiative is part of the broader 21st Century Cures Act - Precision Medicine Initiative and is supported under Assistance Listing 93.368. The All of Us Research Program is a major NIH undertaking aimed at gathering health data from one million or more diverse participants across the United States to enable more individualized approaches to healthcare. The program supports open access to this data for research that advances precision medicine. This funding opportunity is structured to support researcher access to biospecimens stored in the All of Us-supported Biobank. Its purpose is to enable researchers to conduct assays and evaluate the relationships between various biomarkers and chronic diseases. Specific research scopes may include biomarker discovery, validation, novel disease stratification, and multiomics integration related to disease risk, diagnosis, and prognosis. The goal is to enrich the All of Us dataset with additional biological insight for broader research use. The focus on biomarker and omics-based research underlines the program’s aim to foster scientific innovation with direct relevance to precision medicine. Eligible applicants for this opportunity include a wide array of organizations: city, county, and state governments; special district governments; tribal organizations (both Federally recognized and otherwise); public and private institutions of higher education; independent school districts; small and large businesses; nonprofits with or without 501(c)(3) status; eligible federal agencies; U.S. territories; regional organizations; foreign institutions; and faith- or community-based entities. This broad eligibility reflects NIH’s inclusive approach to encourage diverse institutional participation in biomedical research. According to the forecasted timeline, the application period is expected to open on April 1, 2026, and close on June 1, 2026. Awards are anticipated to be issued by September 18, 2026, with the same date marking the start of the funded project period. This indicates a relatively short turnaround between submission and award, which aligns with NIH’s aim to accelerate research implementation. No pre-application stages (such as Letters of Intent or Concept Papers) are required based on the forecast materials. Additionally, the opportunity is not rolling and does not require cost sharing or matching funds. As a federal opportunity with a national scope, this grant does not impose any geographic restrictions within the United States, and applicants from all states and territories are welcome. Researchers and organizations interested in applying are encouraged to contact the All of Us Research Program’s Innovative Collaborations and Ancillary Studies Branch for further information. The designated contact email for queries is [email protected], with instructions to include "AllofUsX01" in the subject line for clarity. This funding opportunity reflects the NIH’s ongoing commitment to supporting translational research that leverages diverse population datasets. The combination of biospecimen access and advanced molecular analysis underscores the NIH’s effort to propel biomedical innovation that can ultimately inform more personalized approaches to health and disease management. Interested applicants should monitor grants.gov for updates, as the opportunity remains in the forecast stage and may be subject to changes before its formal posting.